Literature DB >> 3799691

Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement.

J S Bevan, C W Burke, M M Esiri, C B Adams.   

Abstract

Serum prolactin concentrations and clinical features were correlated with the histopathologic diagnosis in 128 patients, without acromegaly or Cushing's syndrome, referred for surgical treatment of a presumed pituitary adenoma. A serum prolactin concentration of more than 8,000 mU/liter was always due to a prolactin-secreting adenoma. Prolactin levels of less than 8,000 mU/liter occurred with a variety of pathologic diagnoses. Fifteen patients had lesions other than pituitary adenomas, most commonly intrasellar craniopharyngioma; 10 of these had modest hyperprolactinaemia (maximum, 5,260 mU/liter) and four had received inappropriate bromocriptine therapy. Adenomas that were not prolactinomas frequently caused mild hyperprolactinaemia, although this was usually less than 3,000 mU/liter; three of these patients, however, had serum prolactin concentrations greater than this (maximum, 8,000 mU/liter). If the serum prolactin concentration is less than 3,000 mU/liter in the presence of significant pituitary enlargement, surgical removal is essential for both diagnosis and treatment since only prolactin-secreting adenomas are likely to shrink with dopamine agonist therapy. A serum prolactin concentration between 3,000 and 8,000 mU/liter is consistent with any diagnosis, whether the fossa is greatly enlarged or not, and great care must be taken with dopamine agonist therapy in such patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3799691     DOI: 10.1016/0002-9343(87)90373-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

Review 1.  Neurology of the pituitary gland.

Authors:  J R Anderson; N Antoun; N Burnet; K Chatterjee; O Edwards; J D Pickard; N Sarkies
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

Review 2.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 3.  Long-term management of prolactinomas--use of long-acting dopamine agonists.

Authors:  David M Cook
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

4.  Non-Hodgkin lymphoma with panhypopituitarism, hyperprolactinaemia and sixth nerve palsy.

Authors:  J A Shaw; F M Strachan; H A Sawers; J S Bevan
Journal:  J R Soc Med       Date:  1997-05       Impact factor: 5.344

5.  Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect.

Authors:  M S Petakov; S S Damjanović; M M Nikolić-Durović; Z L Dragojlović; S Obradović; M S Gligorović; M Z Simić; V P Popović
Journal:  J Endocrinol Invest       Date:  1998-03       Impact factor: 4.256

Review 6.  Hyperprolactinaemia.

Authors:  M Hartog; M G Hull
Journal:  BMJ       Date:  1988-09-17

7.  The management of pituitary tumours and post-operative visual deterioration.

Authors:  C B Adams
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

8.  Pituitary imaging is essential for women with moderate hyperprolactinaemia.

Authors:  P M Stewart; S Maheshwaran; J Griffith; J Li; M C Sheppard; J Olliff; J A Franklyn
Journal:  BMJ       Date:  1993-02-20

9.  Serum prolactin concentration at presentation of non-functioning pituitary macroadenomas.

Authors:  L A Behan; E P O'Sullivan; N Glynn; C Woods; R K Crowley; T K Tun; D Smith; C J Thompson; A Agha
Journal:  J Endocrinol Invest       Date:  2013-02-04       Impact factor: 4.256

10.  Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients.

Authors:  L Vilar; M C Freitas; L A Naves; L A Casulari; M Azevedo; R Montenegro; A I Barros; M Faria; G C Nascimento; J G Lima; L H Nóbrega; T P Cruz; A Mota; A Ramos; A Violante; A Lamounier Filho; M R Gadelha; M A Czepielewski; A Glezer; M D Bronstein
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.